4/A: Brainstorm Cell Therapeutics CEO Corrects Transaction Code in Amended SEC Filing

Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous SEC Form 4 to correct a transaction code related to a purchase of common stock.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, filed an amended Form 4 with the SEC on July 31, 2024.
• The amendment corrects an error in the original Form 4 filed on May 7, 2024, which incorrectly stated the transaction code.
• The corrected form indicates that 135,000 shares of common stock were purchased on May 6, 2024, at a weighted average price of $0.3753 per share.
• The reporting person directly owns 993,565 shares of common stock following the reported transactions.
• The reporting person may be deemed the beneficial owner of 2,000,847 indirectly owned shares.
• These indirectly owned shares include 1,933,794 shares held by ACCBT Corp. and 67,053 shares held by ACC International Holdings Ltd.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to insider trading activity and provides transparency to investors regarding the transactions of company executives.

Key Dates

Keywords

SEC Form 4, Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, Stock purchase, Beneficial ownership, Amendment